PPAR?-coactivator-1? gene transfer reduces neuronal loss and amyloid-? generation by reducing ?-secretase in an Alzheimer's disease model.
Ontology highlight
ABSTRACT: Current therapies for Alzheimer's disease (AD) are symptomatic and do not target the underlying A? pathology and other important hallmarks including neuronal loss. PPAR?-coactivator-1? (PGC-1?) is a cofactor for transcription factors including the peroxisome proliferator-activated receptor-? (PPAR?), and it is involved in the regulation of metabolic genes, oxidative phosphorylation, and mitochondrial biogenesis. We previously reported that PGC-1? also regulates the transcription of ?-APP cleaving enzyme (BACE1), the main enzyme involved in A? generation, and its expression is decreased in AD patients. We aimed to explore the potential therapeutic effect of PGC-1? by generating a lentiviral vector to express human PGC-1? and target it by stereotaxic delivery to hippocampus and cortex of APP23 transgenic mice at the preclinical stage of the disease. Four months after injection, APP23 mice treated with hPGC-1? showed improved spatial and recognition memory concomitant with a significant reduction in A? deposition, associated with a decrease in BACE1 expression. hPGC-1? overexpression attenuated the levels of proinflammatory cytokines and microglial activation. This effect was accompanied by a marked preservation of pyramidal neurons in the CA3 area and increased expression of neurotrophic factors. The neuroprotective effects were secondary to a reduction in A? pathology and neuroinflammation, because wild-type mice receiving the same treatment were unaffected. These results suggest that the selective induction of PGC-1? gene in specific areas of the brain is effective in targeting AD-related neurodegeneration and holds potential as therapeutic intervention for this disease.
SUBMITTER: Katsouri L
PROVIDER: S-EPMC5087021 | biostudies-literature | 2016 Oct
REPOSITORIES: biostudies-literature
ACCESS DATA